Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Zevra Therapeutics

Evaluate

Thumbnail
April 01, 2021

US FDA approval tracker: March 2021

Thumbnail
March 01, 2021

Go or no go? A delayed decision on Evrenzo

March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.

Article image
Vantage logo
October 05, 2020

Few clues to flotation fever in past performance

Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.

Article image
Vantage logo
September 20, 2018

Attention deficit disorder focus turns to side effects

Limiting abuse and reducing risks are the differentiating factors for projects from Kempharm and Supernus.

Vantage logo
March 14, 2018

Debt comes back to haunt biotech

Vantage logo
April 27, 2017

Interview – Kempharm feels the pain

Vantage logo
January 06, 2017

Select small caps stand out amid wider 2016 stock market declines

Vantage logo
July 07, 2016

Genmab and Tesaro lead first-half gainers as Endo and Infinity falter

Vantage logo
October 09, 2015

Neurocrine’s success sets up showdown of the me-toos

Vantage logo
August 17, 2015

KemPharm opioid project noses ahead

Vantage logo
July 10, 2015

Upcoming events: Late-stage data on CNS drugs from Neurocrine and KemPharm

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up